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In June 1989, we set out to implant 200 albumin-coated aortic bifurcation grafts and to 
track the patients for a period of 5 years to determine whether coating the prosthesis with 
albumin affected the patency or the incidence of complication. Two hundred and one 
prostheses were implanted between June 1989 and July 1991. The primary and secondary 
patency at 5 years was 95% and 98%, respectively. No relation between gender and patency 
or between the state of the runoff and patency was found, but there was a statistically 
significant relation between age and patency (p = 0.00). Graft infection was recorded in 
three patients (1.5%). There were no instances of  bleeding through the graft at the time of  
implantation. The mean intra- and postoperative blood requirement was 2 units. There 
have been no incidences of  false aneurysm in the groin. We conclude that there are no 
disadvantages of  coating the prosthesis with albumin, and a trial of  coated versus uncoated 
prostheses would be impractical. (J VASC SURG 1996;23:686-90.) 
Vascular prostheses made from inert polymers 
were introduced in the 1950s and wcrc originally 
made from Dacron or Teflon woven or knitted into 
tubes. They proved to be satisfactory eplacements for 
the abdominal aorta and iliac arteries in patients with 
extensive arteriosclerosis and occlusions or aneurysms 
of these arteries.~ 
The basic polymers were essentially nonbiode- 
gradable, early complications wcrc t~w (other than 
infcction), and late-stage occlusions were associated 
with poor runoff, progression of disease, or buildup of 
a pseudointimal lining. Such prostheses eldom, if 
ever, healed completely with the formation of a 
confluent neointima, and much of the inner surface 
was covered with a pscudointima composed of fibrin 
and cells. 79 The concept of  making prostheses more 
porous arose from work that equated healing with 
porosity, and the idea of a porous lattice through 
which a microcapillary network could nourish a 
functioning neointima was attractive. ~~ The draw- 
back was that the porous prostheses had to bc 
prcclottcd at the time of implantation.12 
Coating a Dacron velour prosthesis with a biode- 
gradable substance that renders it temporarily imper- 
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meable has been shown to reduce blccding at implan 
tation.1316 Such a coating should reduce blood loss at 
implantation without introducing other complica 
tions, e.g., late-stage bleeding when the coating is 
absorbed, increase in infection rate, reduction in 
patcncy, and increase in false ancurysms, and it should 
not render the polymer biodegradable. 
We know that the long-term patency rate of aortic 
bifurcation grafts is excellent. 17'l~ What we do not 
know is whether by incorporating a biodegradable 
coating with a prosthesis the incidence of  infection 
will be altered, more false ancurysms may arise, or 
how long-term patency will be affected. Several clini 
cal studies have been carried out by using collagen or 
gelatin as a coating, but no long-term studies on 
albumin-coated grafts are available.19'2~ 
We have monitored 199 patients who had an 
albumin-coated knitted Dacron prosthesis inserted 
between June 1989 and July 1991. Our aim was to 
find out whether the incidence of  complications was 
similar to what we could anticipate from our own 
experience and historic comparisons. 
PAT IENTS AND METHODS 
From June 1989 to July 1991, 201 human albu 
min-coated Dacron knitted velour prostheses (Bard 
VSCI, Billerica, Mass.) were used to bypass the aorta 
and iliac arteries in 201 patients. Only occasionally 
was anything other than a 16 mm x 8 mm bifurcation 
graft used (range 16 to 20 mm). There were 151 men 
(75%) and 50 women (25%) whose ages ranged from 
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31 to 84 years, with a mean of 65.8 years. One 
hundred and two operations were perfi)rincd fbr 
arteriosclerotic occlusive disease, and thc remaining 
99 were fbr abdominal aortic aneurysms. All opera- 
tions wcrc done in one unit, and the method of 
preparation and operation were the same in all opera- 
tions. Operations perfbrmed Ibr ruptured aortic an- 
curysms were excluded. 
In all cases the skin was washed and painted with 
iodine but not shaved. In the operating room the skin 
was shaved, ifnecessary, then prcparcd with an alcohol 
solution of hibitane, then iodine. All patients were 
given a second-generation cephalosporin, 750 nag IV, 
at the time the anesthetic was administered. Patients 
were not given heparin systematically during the 
operation. The aorta was invariably exposed through 
a transverse abdominal incision. In all patients the 
proximal end of the prosthesis was sewn end-to-end 
to the aorta, then either end-to-end to the common 
lilac arteries or end-to-side to the common femoral 
arteries. 
Antibiotics were continued after surgery, 750 mg 
IV at 12 and 24 hours. We recommended that all 
patients take 100 mg of aspirin daily from the date of 
discharge. Patients were evaluated at 6 weeks and at 3 
months after operation, then at intervals of 6 months. 
The duration of tbllow-up varied from 6 years to 4 
years. Mean fbllow-up time was 57 months. 
Notes wcrc made of any excessive blccding at 
operation, leaking from the surface of the prostheses, 
and transfusion rcquircmcnts. Wc looked for evidence 
of inlkction involving the prostheses, postoperative 
bleeding, the tbrmation of thlsc ancurysms in the 
groin, and patcncy. Patency was described as primary 
or secondary according to the criteria expressed in the 
Ad Hoc Committee on Reporting Standards. 2~ Cox's 
regression analysis was used tbr statistical analysis of 
the collected ata. 
RESULTS 
In the vast majority of patients, a 16 • 8 mm bifur- 
cation graft was used. In 17 operations we used an 
18 x 9 mm prosthesis and in fbur operations a 
20 • 10 mm prosthesis. Wc used 4-0 Prolene (Ethi- 
con, Ltd; Edinburgh, U.K.) for all anastomoses. Two 
patients died from myocardial inl~hrction within 28 
days of operation, leaving 199 patients available tbr 
follow-up. Of  these, 102 had operations fbr arterio- 
sclerotic occlusive disease, and 97 had aneurysms-- 
i.e., 97 aortobiiliac grafts and 102 aortobitkmoral 
grafts. 
Intraoperat ive blood loss. There were no in- 
stances of bleeding through a prosthesis at the time of 
implantation. No bleeding occurred through any of 
the prostheses at the site at which clamps had been 
applied. Two patients had to bc returned to surgery 
from the recovery room because of postoperative 
bleeding. In both patients, bleeding was from the 
suture line, not from the graft or from a needle 
ptmcture in the graft. 
An average of 2 units of blood was given (mean 
intra- and postoperative r quirement) to those pa 
ticnts who received blood transfusions (119), and no 
blood transfusion was given during or after surgery in 
82 patients. 
Infection. Evidence of infection in one groin was 
found in three patients and involved the prosthesis 
( 1.5%). All these patients were in the arteriosclcrotic 
occlusive disease group. One occurred 4 weeks after 
surgery and was caused by a mcthicillin-rcsistant 
staphylococcus aureus. The complication was trcatcd 
by giving the patient rit~mpacin and covering the 
prosthesis with sartorius muscle. The infection re- 
solved, and the graft remains patent 52 inonths after 
this episode. The second patient showed signs of 
infection in the groin 3 months after surgery. The 
infection responded to drainage, irrigation with io- 
dine, and antibiotics. The graft was patent at the last 
fbllow-up, 41/2 years a[~cr implantation. In the third 
patient, infection appeared to start 7 inonths at~er 
implantation; it failed to respond to antibiotics, and 
the prosthesis was removed and replaced with an 
axillobifcmoral graft. 
Patency. Only 10 patients had occlusion in onc or 
the other limb of the bifurcated graft. Overall primary 
patency rate was 98%. All 10 patients were in the 
occlusive disease group. Fig. 1 shows, in the fbrm of 
a life table, the diftkrencc in patcncy with time of the 
grafts in patients who had arteriosclerosis/occlusion 
and those who had aneurysms. Thc lincs have bccn 
discontinued at the point where the number of 
observations fell below 20. 
We recorded an occlusion of the superficial femo- 
ral artery distal to a reconstruction in 41 patients 
(41%) in the occlusive disease group. Of  the l0 pa- 
tients who had an occlusion, five had a blocked super 
ficial tkmoral artery on the ipsilatcral side. There was 
no statistically significant correlation between occlu- 
sion of a prosthesis and an occluded superficial fEmo 
ral artery (Fig. 2). If we used limbs of bifurcation 
grafts rather than patients, the denominator in the 
occlusive disease group increases to 204, an inci- 
dence of occlusion of 5% in the group. Six of the l0 
occlusions occurred approximately 3 years after op 
eration. 
Eight of the 10 occlusions were in male patients; 
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Fig. 1. Survival curve for diagnosis. Life table analysis-- 
proportion of patients with occlusion vs time. Two groups 
based on diagnosis (aneurysm or arteriosclerosis). All fig- 
ures indicate number of observations ateach time interval. 
1.0 
0 
_~ o.9 
-6 
o 0.8 
0 
t -  
~ 0.7 
~ 0.6 
L . .  
0 
" 0.5 
0 _ _  
i , . .  
1'3 - - - -  
0.4 
1 
I 
I -  l 
i - - =  SF  Patent  j 
52 134 96 53 15 13 9 
43 35 22 6 6 2 
J i i i i i i 
10 20 30 40 50 60 70 
Time in Months 
Fig. 2. Survival curve for superficial femoral artery occlu- 
sion. Two groups of patients with occlusion in superficial 
femoral artery on ipsilateral side and patients with patent 
superficial femoral arteries. 
there was no relation between gender and occlusion 
(Fig. 3). Age, however, did have a statistically signifi- 
cant effect on occlusion; the older the patient, the less 
the risk of occlusion (p--0.00) (Fig. 4). Of  the 10 
occluded grafts, patency was successfully restored in 7 
patients (two patients by thrombectomy alone; 3 
patients by thrombectomy and femoropopliteal 
bypass; 2 patients by extending the occluded limb of 
the graft from the iliac to the common femoral 
artery). The secondary patency rate was therefore 
98.0%. 
D ISCUSSION 
If by coating a prosthesis with a biodegradable 
substance (e.g., human serum albumin) one can 
reduce blood loss and avoid transfusion, the propo- 
sition is attractive to both surgeon and patient. It 
becomes less attractive, however, if the advantages are 
offset by an increased incidence of complications and 
reduction in long-term patency. 
We chose not to do a randomized comparative 
trial because without knowing the incidence of com- 
plications we could not predict how many patients 
we might need. We anticipated that differences were 
likely to be small, and that to be certain of any 
difference at the 90% confidence level, we would 
probably need >2500 patients in each arm of a trial. 
In the period set for the study, June 1989 to July 
1991, we performed 201 aortic bifurcation grafts, 
which fulfilled the criteria for our study. We excluded 
patients who had emergency aortic surgery on the 
basis that some patients may have a coagulinopathy, 
and there was no preoperative skin preparation. We 
also excluded patients who had tube grafts and 
patients who had thoracoabdominal aneurysms, and 
hence very extensive grafts. Two patients had a 
myocardial infarction within 28 days of operation and 
died as a result. Because there were no immediate 
intraoperative complications a sociated with the pros- 
thesis and because these patients were unavailable for 
long-term follow-up, we excluded them from the 
analysis. Nine patients had clinical or electrocardio- 
graphic evidence of  an infarct within the first 28 days; 
they recovered fully and were included in the analysis. 
The incidence of myocardial infarction does not differ 
from that reported for similar operations in the 
preceding 4 years in our unit. 22 In this study of 
patients who had an aortic bifurcation graft, there 
were too few occlusions to allow us to perform 
multivariate analysis. Instead, we examined four co- 
variates to test for a relation between the patient's 
gender, age, and underlying reason for operation 
(occlusion or aneurysm), to the patency rate of the 
superficial femoral artery and the incidence of com- 
plications. Although all 10 occlusions occurred in the 
occlusive disease group, the difference between the 
incidence of occlusion in the occlusive disease group 
compared with the aneurysm group was significant 
only at the 10% level (p = 0.62). 
The long-term patency rate compares favorably 
with the results reported for other coated prosthe- 
ses a9,2~ and agrees with the short-term results re- 
ported by Branchereau et al. ]6 who used similar 
prostheses. 
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Fig. 3. Survival curve for gender. Two groups on basis of  
gender. 
The results are also comparable with those re- 
ported from our unit when we used uncoated pros- 
theses./7 We found that age influenced the long-term 
patency of the grafts--the older the patient, the less 
likely the graft was to thrombose. However, all 
patients in the 71 to 84 age group had aneurysms, and 
it is likely that this finding reflects the reason for 
operation rather than some protective factor related 
to age. We know of  no instances of aneurysmal 
dilatation of the prostheses or leakage that have 
occurred after an interval of time and that might 
indicate biodegradation f the polymer. 
This series of 199 patients had a 1.5% incidence of 
graft infection, which could be expected when look- 
ing at the incidence of infizction in vascular sur- 
gery. 1 ]-] 3 No correlation between infection and any of 
the covariates we studied was found. So far, after a 
mean follow-up period of 4 years, there have been no 
false aneurysms at the junction between prosthesis 
and common femoral artery. By false aneurysm, we 
refer to the type that occurs without evidence of local 
infection to differentiate them from infected cases. 
Theoretically it may be possible to contract a viral 
infection from coatings derived from human serum 
albumin. We are not aware of any such infection 
having occurred in this group of patients. However, 
it is unlikely that a patient who contracted the human 
immunodeficiency virus (HIV) would show any 
clinical manifestations sofar, and we have not tested 
for this possibility. We have not seen any patient 
contract hepatitis after insertion of a coated pros- 
thesis. Transmission of a virus seems highly unlikely 
because the albumin used for coatings must meet 
stringent quality control standards and must be ob- 
tained from donors tested for HIV and hepatitis. The 
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Fig. 4. Survival curve for age. 
commercial preparation of coated grafts involves 
sterilization. 
We concluded that the albumin-coated prosthesis 
provided the advantage of minimal blood loss without 
preclotting and did not pale in comparison with 
uncoated prostheses regarding infection, durability, 
and long-term patency. No apparent difference in 
patency was found between this series of albumin- 
coated grafts and a series of uncoated grafts previously 
published from this unit. We calculate that in view of 
the high patency rate, a trial of a coated graft against 
an uncoated graft would be impractical and is 
unnecessary. 
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